Indicates management contract or compensatory plan. 2020 Incentive Award Plan.įorm of Stock Option Grant Notice and Stock Option Agreement under the 2020 Incentive Award Plan.ĤD Molecular Therapeutics, Inc.
#Zip code for 4d molecular therapeutics registration#
Power of Attorney (included in the signature page to this registration statement).ĤD Molecular Therapeutics, Inc. Registration statement as awards under the plans are exercised and/or vest.Īmended and Restated Certificate of Incorporation of 4D Molecular Therapeutics, Inc.Īmended and Restated Bylaws of 4D Molecular Therapeutics, Inc.Ĭonsent of Latham & Watkins LLP (included in Exhibit 5.1).Ĭonsent of Independent Registered Public Accounting Firm. Proposed sale to take place as soon after the Nasdaq Global Select Market on March 24, 2021, which was $41.24. The Proposed Maximum Offering Price Per Share for shares available for future grant under the ESPP is the average of the high and low prices for the registrants common stock as reported on the Resulting from an annual increase as of January 1, 2021.įor purposes of calculating the registration fee. Represents the additional shares of common stock available for future issuance under the Registrants ESPP The Nasdaq Global Select Market on March 24, 2021, which was $41.24. The Proposed Maximum Offering Price Per Share for shares available for future grant under the 2020 Plan is the average of the high and low prices for the registrants common stock as reported on This estimate is made pursuant to Rule 457(c) and Rule 457(h) of the Securities Act solelyįor purposes of calculating the registration fee. Plan resulting from an annual increase as of January 1, 2021. Represents the additional shares of common stock available for future issuance under the Registrants 2020 Registration statement shall also cover any additional shares of the Registrants common stock that become issuable under the 2020 Incentive Award Plan (the ∲020 Plan) and the 2020 Employee Stock Purchase Plan (the ∾SPP)īy reason of any stock dividend, stock split, recapitalization or similar transaction effected without the Registrants receipt of consideration which would increase the number of outstanding shares of common stock. Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the Securities Act), this ☐Ĭommon Stock, par value $0.0001 per share If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition periodįor complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. See the definitions of large acceleratedįiler, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act. The registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
#Zip code for 4d molecular therapeutics zip#
(Name, address, including zip code, and telephone number, including area code, of agent for service)
(Address, including zip code, of registrants principal executive offices) (Exact name of registrant as specified in its charter) As filed with the Securities and Exchange Commission on March 25, 2021
0 kommentar(er)
